Elutia (NASDAQ:ELUT – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Wednesday, August 7th.
Elutia (NASDAQ:ELUT – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter. The business had revenue of $6.69 million during the quarter.
Elutia Price Performance
Shares of ELUT traded up $0.16 during midday trading on Wednesday, hitting $3.79. The stock had a trading volume of 863 shares, compared to its average volume of 40,639. The company has a 50 day simple moving average of $3.84 and a two-hundred day simple moving average of $3.51. Elutia has a twelve month low of $1.10 and a twelve month high of $5.24. The firm has a market cap of $91.98 million, a price-to-earnings ratio of -1.53 and a beta of 0.72.
Analyst Ratings Changes
View Our Latest Stock Report on ELUT
About Elutia
Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.
See Also
- Five stocks we like better than Elutia
- What Does Downgrade Mean in Investing?
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How to Calculate Inflation Rate
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.